Two Struggling Stocks Poised for a Potential Comeback
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 03 2025
0mins
Source: NASDAQ.COM
Novo Nordisk's Growth Potential: Novo Nordisk has several upcoming catalysts, including late-stage studies for CagriSema and a potential oral semaglutide formulation, which could significantly boost its revenue and market position.
Regeneron's Resilience: Despite facing biosimilar competition for Eylea, Regeneron has shown strong financial results, with a 1% revenue growth and promising developments in its product pipeline, including Dupixent and a new cancer therapy, Lynozyfic.
Investment Opportunities: Both Novo Nordisk and Regeneron are considered attractive investment options due to their potential for recovery and growth, especially as Novo Nordisk's stock is currently undervalued.
Stock Advisor Recommendations: The Motley Fool's Stock Advisor has identified other stocks as top picks, suggesting that while Novo Nordisk is recommended, it did not make the top 10 list, which has historically yielded significant returns for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 44.390
Low
42.00
Averages
54.67
High
70.00
Current: 44.390
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Q1 Earnings Preview Amidst Competitive Landscape
- Intensifying Market Competition: Novo Nordisk is set to report Q1 earnings on May 6, with consensus EPS at $1.10 and revenue at $11.26 billion, but three downward revisions in the past three months indicate increasing competitive pressure on its GLP-1 drug franchise.
- Strong Prescription Demand: Early demand for Novo's oral semaglutide (Wegovy) has been robust, with over 600,000 prescriptions written in the first two months, suggesting a potential outpacing of Eli Lilly's competing offerings in the market.
- Pricing Strategy Adjustments: In response to market pressures, Novo plans to cut U.S. list prices for Wegovy, Ozempic, and Rybelsus by approximately 35%-50%, aiming to expand market share and improve accessibility, although this may compress margins in the short term.
- Strategic Partnership Development: Novo's collaboration with Hims & Hers Health will see the platform offer Novo's branded GLP-1 drugs while discontinuing compounded alternatives, which could reduce gray-market competition and enhance Novo's brand positioning in the market.
See More
Amazon's New Logistics Initiative Shakes Market
- Increased Market Competition: Amazon's announcement of a new initiative allowing external businesses to utilize its supply chain for deliveries led to significant stock declines for UPS and FedEx, dropping over 10% and 9% respectively, indicating investor concerns about intensified competition in the logistics sector.
- Strong Sales Growth: Palantir reported an impressive 85% revenue growth in Q1, with net income approximately quadrupling year-over-year, showcasing its robust performance in the defense technology sector and projecting a doubling of its U.S. business in the coming year.
- Tesla and SEC Settlement: Tesla CEO Elon Musk reached a settlement with the SEC, agreeing to pay $1.5 million in penalties over allegations of failing to disclose his Twitter stake prior to acquisition, although this minor fine is not expected to have a significant financial impact on the company.
- GLP-1 Market Dynamics: Novo Nordisk's Wegovy pill has rapidly gained tens of thousands of new users within four months of launch, while Eli Lilly's competing Foundayo has seen a more modest uptake, reflecting a shift in market demand for weight-loss medications.
See More
Amazon's New Logistics Initiative Shakes Market
- Market Uncertainty Intensifies: Rising tensions in the Middle East have led to surging oil prices, causing the Dow Jones Industrial Average to drop over 550 points on Monday, marking its worst performance in more than a month, which has left investors concerned about future market sentiment.
- Palantir Surpasses Expectations: Palantir reported an 85% revenue growth in Q1, with net income nearly quadrupling year-over-year, and anticipates its U.S. business will double again next year, raising its full-year free cash flow guidance to $4.2 billion to $4.4 billion, indicating strong market demand and growth potential.
- Tesla Settles with SEC: Tesla CEO Elon Musk has agreed to pay $1.5 million to the SEC to settle allegations of failing to disclose his stake in Twitter before its acquisition, which, if approved by the judge, could alleviate legal risks for Musk and potentially have a positive impact on Tesla's stock price.
- Amazon's New Logistics Initiative: Amazon announced a new initiative allowing external businesses to utilize its supply chain networks for deliveries, which has raised concerns about increased competition with UPS and FedEx, leading to stock declines of over 10% and 9% respectively, reflecting market apprehension about the new competitive landscape.
See More
Three Growth Stocks to Consider Now
- Novo Nordisk's Challenges and Opportunities: Despite a 36% drop in share price over the past year, Novo Nordisk maintains strong profitability with a 33% gross margin and powerful assets like Ozempic and Wegovy, positioning it to benefit from growth in the GLP-1 market in the future.
- PDD Holdings' Market Potential: PDD Holdings has seen a 12% decline in stock price over the past year, yet reported a 12% revenue growth in the last three months of 2025, demonstrating resilience amid economic uncertainty, with Temu's popularity providing a foundation for future recovery.
- Intuit's Value Recovery: Although Intuit's stock has fallen 36% in the past year, its latest quarterly results show a 17% revenue increase, and its strong brand presence in accounting and tax software suggests it can leverage AI to enhance value moving forward.
- Investor Patience Rewarded: These three stocks currently have forward P/E ratios of 13, 8, and 15 respectively, indicating their investment value in the current market environment, with long-term holding potentially yielding significant returns for investors.
See More
Investor Sentiment on Viking Therapeutics Amid Market Volatility
- Optimistic Market Outlook: Despite a 15% decline in Viking Therapeutics' stock this year, Wall Street remains optimistic, projecting a 207% increase over the next 12 months with a price target of $92.33, reflecting confidence in its growth potential.
- Obesity Drug Development: Viking is developing the anti-obesity drug VK2735, currently undergoing two phase 3 clinical trials for obese patients with and without diabetes, where positive results could serve as a significant catalyst for stock price appreciation.
- Massive Market Demand: With obesity rates in the U.S. estimated at around 40% by the CDC and potentially as high as 70% according to recent studies, there exists a substantial unmet need in the obesity drug market that Viking aims to address with its products.
- Risks and Opportunities: While Viking faces competition from major pharmaceutical companies like Eli Lilly and Novo Nordisk, successful clinical trial outcomes for VK2735 could yield substantial market rewards, though investors should be wary of the stock's inherent volatility.
See More
Oil Prices Surge Amid Iran Tensions; Eli Lilly Stock Volatility
- Oil Price Surge: Oil prices spiked as the UAE reported missile and drone attacks from Iran, with WTI crude rising approximately $3 to $105 per barrel and Brent crude increasing about $6 to $114 per barrel, which could exacerbate global economic uncertainty and inflation expectations.
- Interest Rate Increase: The yield on the 10-year Treasury jumped to around 4.45% and the 30-year yield crossed above 5%, with the odds of a rate hike by year-end rising from 23% to 36%, indicating a shift in market expectations regarding Federal Reserve policy that may impact investor confidence.
- Eli Lilly Stock Volatility: Eli Lilly's stock experienced significant volatility after the FDA reported a patient experiencing liver failure following the use of its obesity drug Foundayo, causing shares to drop nearly $15, although the company later clarified that the adverse event was not related to the drug, leading to a recovery in stock price, highlighting market sensitivity to drug safety issues.
- Market Response: Although Foundayo's initial market performance has not matched Novo Nordisk's Wegovy, over 20,000 people have started using the medication, with more than 80% being new GLP-1 users, indicating potential growth for Foundayo in the market, with expectations for improved sales in the second half of the year.
See More
Novo Nordisk Q1 Earnings Preview Amidst Competitive Landscape
- Intensifying Market Competition: Novo Nordisk is set to report Q1 earnings on May 6, with consensus EPS at $1.10 and revenue at $11.26 billion, but three downward revisions in the past three months indicate increasing competitive pressure on its GLP-1 drug franchise.
- Strong Prescription Demand: Early demand for Novo's oral semaglutide (Wegovy) has been robust, with over 600,000 prescriptions written in the first two months, suggesting a potential outpacing of Eli Lilly's competing offerings in the market.
- Pricing Strategy Adjustments: In response to market pressures, Novo plans to cut U.S. list prices for Wegovy, Ozempic, and Rybelsus by approximately 35%-50%, aiming to expand market share and improve accessibility, although this may compress margins in the short term.
- Strategic Partnership Development: Novo's collaboration with Hims & Hers Health will see the platform offer Novo's branded GLP-1 drugs while discontinuing compounded alternatives, which could reduce gray-market competition and enhance Novo's brand positioning in the market.
See More
Amazon's New Logistics Initiative Shakes Market
- Increased Market Competition: Amazon's announcement of a new initiative allowing external businesses to utilize its supply chain for deliveries led to significant stock declines for UPS and FedEx, dropping over 10% and 9% respectively, indicating investor concerns about intensified competition in the logistics sector.
- Strong Sales Growth: Palantir reported an impressive 85% revenue growth in Q1, with net income approximately quadrupling year-over-year, showcasing its robust performance in the defense technology sector and projecting a doubling of its U.S. business in the coming year.
- Tesla and SEC Settlement: Tesla CEO Elon Musk reached a settlement with the SEC, agreeing to pay $1.5 million in penalties over allegations of failing to disclose his Twitter stake prior to acquisition, although this minor fine is not expected to have a significant financial impact on the company.
- GLP-1 Market Dynamics: Novo Nordisk's Wegovy pill has rapidly gained tens of thousands of new users within four months of launch, while Eli Lilly's competing Foundayo has seen a more modest uptake, reflecting a shift in market demand for weight-loss medications.
See More
Amazon's New Logistics Initiative Shakes Market
- Market Uncertainty Intensifies: Rising tensions in the Middle East have led to surging oil prices, causing the Dow Jones Industrial Average to drop over 550 points on Monday, marking its worst performance in more than a month, which has left investors concerned about future market sentiment.
- Palantir Surpasses Expectations: Palantir reported an 85% revenue growth in Q1, with net income nearly quadrupling year-over-year, and anticipates its U.S. business will double again next year, raising its full-year free cash flow guidance to $4.2 billion to $4.4 billion, indicating strong market demand and growth potential.
- Tesla Settles with SEC: Tesla CEO Elon Musk has agreed to pay $1.5 million to the SEC to settle allegations of failing to disclose his stake in Twitter before its acquisition, which, if approved by the judge, could alleviate legal risks for Musk and potentially have a positive impact on Tesla's stock price.
- Amazon's New Logistics Initiative: Amazon announced a new initiative allowing external businesses to utilize its supply chain networks for deliveries, which has raised concerns about increased competition with UPS and FedEx, leading to stock declines of over 10% and 9% respectively, reflecting market apprehension about the new competitive landscape.
See More
Three Growth Stocks to Consider Now
- Novo Nordisk's Challenges and Opportunities: Despite a 36% drop in share price over the past year, Novo Nordisk maintains strong profitability with a 33% gross margin and powerful assets like Ozempic and Wegovy, positioning it to benefit from growth in the GLP-1 market in the future.
- PDD Holdings' Market Potential: PDD Holdings has seen a 12% decline in stock price over the past year, yet reported a 12% revenue growth in the last three months of 2025, demonstrating resilience amid economic uncertainty, with Temu's popularity providing a foundation for future recovery.
- Intuit's Value Recovery: Although Intuit's stock has fallen 36% in the past year, its latest quarterly results show a 17% revenue increase, and its strong brand presence in accounting and tax software suggests it can leverage AI to enhance value moving forward.
- Investor Patience Rewarded: These three stocks currently have forward P/E ratios of 13, 8, and 15 respectively, indicating their investment value in the current market environment, with long-term holding potentially yielding significant returns for investors.
See More
Investor Sentiment on Viking Therapeutics Amid Market Volatility
- Optimistic Market Outlook: Despite a 15% decline in Viking Therapeutics' stock this year, Wall Street remains optimistic, projecting a 207% increase over the next 12 months with a price target of $92.33, reflecting confidence in its growth potential.
- Obesity Drug Development: Viking is developing the anti-obesity drug VK2735, currently undergoing two phase 3 clinical trials for obese patients with and without diabetes, where positive results could serve as a significant catalyst for stock price appreciation.
- Massive Market Demand: With obesity rates in the U.S. estimated at around 40% by the CDC and potentially as high as 70% according to recent studies, there exists a substantial unmet need in the obesity drug market that Viking aims to address with its products.
- Risks and Opportunities: While Viking faces competition from major pharmaceutical companies like Eli Lilly and Novo Nordisk, successful clinical trial outcomes for VK2735 could yield substantial market rewards, though investors should be wary of the stock's inherent volatility.
See More
Oil Prices Surge Amid Iran Tensions; Eli Lilly Stock Volatility
- Oil Price Surge: Oil prices spiked as the UAE reported missile and drone attacks from Iran, with WTI crude rising approximately $3 to $105 per barrel and Brent crude increasing about $6 to $114 per barrel, which could exacerbate global economic uncertainty and inflation expectations.
- Interest Rate Increase: The yield on the 10-year Treasury jumped to around 4.45% and the 30-year yield crossed above 5%, with the odds of a rate hike by year-end rising from 23% to 36%, indicating a shift in market expectations regarding Federal Reserve policy that may impact investor confidence.
- Eli Lilly Stock Volatility: Eli Lilly's stock experienced significant volatility after the FDA reported a patient experiencing liver failure following the use of its obesity drug Foundayo, causing shares to drop nearly $15, although the company later clarified that the adverse event was not related to the drug, leading to a recovery in stock price, highlighting market sensitivity to drug safety issues.
- Market Response: Although Foundayo's initial market performance has not matched Novo Nordisk's Wegovy, over 20,000 people have started using the medication, with more than 80% being new GLP-1 users, indicating potential growth for Foundayo in the market, with expectations for improved sales in the second half of the year.
See More
